<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088800</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01-06</org_study_id>
    <nct_id>NCT03088800</nct_id>
  </id_info>
  <brief_title>IBUPAP Study for Pain Management in Children</brief_title>
  <official_title>IBUPAP - Combination of Oral Ibuprofen and Acetaminophen (APAP) is Superior to Either Analgesic Alone for Pediatric Emergency Department (ED) Patients With Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current literature supports ibuprofen and APAP are the most commonly used analgesics in the&#xD;
      pediatric ED for acute traumatic/non-traumatic pain. However, the analgesic benefits of&#xD;
      combination ibuprofen and APAP in this specific setting does not exist, but instead only as&#xD;
      it applies to pediatric patients with postoperative pain. Thus, we have designed a&#xD;
      double-blind, randomized, controlled clinical trial to evaluate analgesic efficacy, safety&#xD;
      and feasibility of combination therapy to potentially broaden its clinical application in the&#xD;
      pediatric ED. The investigators' hypothesize that combination oral ibuprofen and APAP therapy&#xD;
      is superior to either drug alone and is an excellent analgesic modality for controlling acute&#xD;
      traumatic/non-traumatic pain in the pediatric ED.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' hypothesize the combination of oral ibuprofen and acetaminophen (APAP) is&#xD;
      superior to either analgesic alone plus placebo for pediatric emergency department patients&#xD;
      with acute traumatic/non-traumatic pain&#xD;
&#xD;
        1. Intent to Treat, prospective, randomized, double-blind trial.&#xD;
&#xD;
        2. Primary outcome: Pain reduction via NRS/FACES pain scale at times 0 and 60 minutes from&#xD;
           administration of medication(s).&#xD;
&#xD;
           Secondary outcomes: Antipyretic effects, level of analgesia achieved with each patient&#xD;
           diagnosis(es), incidence and type of adverse effect(s), and patients' and parents'&#xD;
           satisfaction with achieved level of analgesia.&#xD;
&#xD;
        3. Population : ages 3 - 17. Sample size 90 patients (30 per arm). Group 1: oral ibuprofen&#xD;
           at 10mg/kg dose and placebo of equal volume; Group 2: oral APAP at 15 mg/kg dose and&#xD;
           placebo of equal volume; and, Group 3: oral ibuprofen at 10 mg/kg dose and APAP at&#xD;
           15mg/kg dose.&#xD;
&#xD;
        4. Location: Urban tertiary care hospital Pediatric ED with 40,000 annual departmental&#xD;
           visits.&#xD;
&#xD;
        5. Duration of Enrollment: 1 year from commencement of the study.&#xD;
&#xD;
      6/7. Patients will be enrolled and randomized upon triage by an assigned nurse dedicated to&#xD;
      the study into one of three groups by using a blocks-randomization scheme for every 15&#xD;
      patients maintained by the ED pharmacists.&#xD;
&#xD;
      8. For patients experiencing breakthrough pain, oral morphine sulfate at 0.2mg/kg will be&#xD;
      provided.&#xD;
&#xD;
      Group 1: oral ibuprofen at 10 mg/kg dose and placebo of equal volume;&#xD;
&#xD;
      Group 2: oral APAP at 15 mg/kg dose and placebo of equal volume; and,&#xD;
&#xD;
      Group 3: oral ibuprofen at 10 mg/kg dose and APAP at 15mg/kg dose. Medications including&#xD;
      placebo will be given via prefilled syringes of identical volume, color and flavor. Level of&#xD;
      analgesia will be assessed at times 0 and 60 minutes from administration of medication(s).&#xD;
&#xD;
      All enrolled patients, health care practitioners, and research associates will be blinded to&#xD;
      the study medication(s) given and to the allocation sequence. Pharmacist(s) who are aware of&#xD;
      the study medication(s) will not enroll patients. The allocation sequence code will only be&#xD;
      revealed to the researchers once recruitment, data collection, and data entry are completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Pain Score via Numeric Rating Scale or FACES pain scale at 60 minutes from baseline ( ranging from 0 to 10, with 0 being no pain, 5 being moderate pain, and 10 being very severe pain)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Oral Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral APAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral APAP at 15 mg/kg and placebo of equal volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Oral Ibuprofen at 10 mg/kg dose</description>
    <arm_group_label>Oral Ibuprofen</arm_group_label>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP</intervention_name>
    <description>Oral APAP at 15mg/kg dose</description>
    <arm_group_label>Oral APAP</arm_group_label>
    <arm_group_label>Oral Ibuprofen and Oral APAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ages 3-17 years old presenting to the pediatric ED&#xD;
&#xD;
          -  treating physician deems patient required ibuprofen Tylenol or both for pain relief&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  documented or suspected pregnancy, (2)&#xD;
&#xD;
          -  parental refusal,&#xD;
&#xD;
          -  allergies to NSAIDS or APAP&#xD;
&#xD;
          -  inability to tolerate oral medications or contraindications to oral medication route&#xD;
&#xD;
          -  received analgesics within 4 hours prior to ED presentation&#xD;
&#xD;
          -  inability to use pain scales&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 18, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <results_first_submitted>January 20, 2021</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03088800/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Ibuprofen</title>
          <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose</description>
        </group>
        <group group_id="P2">
          <title>Oral APAP</title>
          <description>Oral APAP at 15 mg/kg and placebo of equal volume&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
        <group group_id="P3">
          <title>Oral Ibuprofen and Oral APAP</title>
          <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Ibuprofen</title>
          <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose</description>
        </group>
        <group group_id="B2">
          <title>Oral APAP</title>
          <description>Oral APAP at 15 mg/kg and placebo of equal volume&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
        <group group_id="B3">
          <title>Oral Ibuprofen and Oral APAP</title>
          <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.20" spread="4.48"/>
                    <measurement group_id="B2" value="10.90" spread="3.98"/>
                    <measurement group_id="B3" value="12.17" spread="3.67"/>
                    <measurement group_id="B4" value="11.42" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at 60 Minutes</title>
        <description>Pain Score via Numeric Rating Scale or FACES pain scale at 60 minutes from baseline ( ranging from 0 to 10, with 0 being no pain, 5 being moderate pain, and 10 being very severe pain)</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ibuprofen</title>
            <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose</description>
          </group>
          <group group_id="O2">
            <title>Oral APAP</title>
            <description>Oral APAP at 15 mg/kg and placebo of equal volume&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
          </group>
          <group group_id="O3">
            <title>Oral Ibuprofen and Oral APAP</title>
            <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 60 Minutes</title>
          <description>Pain Score via Numeric Rating Scale or FACES pain scale at 60 minutes from baseline ( ranging from 0 to 10, with 0 being no pain, 5 being moderate pain, and 10 being very severe pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="2.15"/>
                    <measurement group_id="O2" value="3.10" spread="1.92"/>
                    <measurement group_id="O3" value="2.77" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Ibuprofen</title>
          <description>Oral Ibuprofen at 10mg/kg dose and placebo of equal volume&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose</description>
        </group>
        <group group_id="E2">
          <title>Oral APAP</title>
          <description>Oral APAP at 15 mg/kg and placebo of equal volume&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
        <group group_id="E3">
          <title>Oral Ibuprofen and Oral APAP</title>
          <description>Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.&#xD;
Ibuprofen: Oral Ibuprofen at 10 mg/kg dose&#xD;
APAP: Oral APAP at 15mg/kg dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sergey Motov, MD</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>7182836000</phone>
      <email>smotov@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

